A retrospective study involving 23 patients with advanced NSCLC and ALK rearrangements treated with ICI monotherapy reported a poor response: the median PFS was approximately 3 months, and nearly 70% of patients experienced disease progression after ICI monotherapy [29]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.